Cancer Immunology &Immunotherapy Research in the Cancer Immunology &Immunotherapy Program is exploring basic, translational and clinical aspects of lymphoid malignancies and various approaches to cancer immunotherapy. The overall goal of the members of the program is to improve our understanding of the mechanisms of immune system-based cell signaling, differentiation, trafficking, and death with the long-term goal of enhancing our ability to treat lymphoid malignancies and induce a more effective anti-cancer immune response. The program also focuses on translating laboratory advances to the clinic through innovative clinical trials in cancer immunotherapy. There are two major overlapping themes within the Program. The first Theme is Cancer Immunology. The emphasis within this Theme is basic research in Lymphocyte Signaling, Host Responses, and Stem Cell Biology. The emphasis of the complementary translational Cancer Immunotherapy Theme is upon Immunotherapy of Lymphoid Malignancies and Cancer Vaccines. Major accomplishments of the Cancer Immunology and Immunotherapy Program over the past funding period include understanding the roles of signaling molecules, including TNFR-associated factors (TRAFs), in lymphoid malignancies, analysis of the mechanisms of action of ahti-CD20 therapeutic antibodies, development of TLR9 agonists as immunotherapeutic agents, and development of a prostate cancer vaccine. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. Most notable are the collaborative, translational studies taking place through the Lymphoma SPORE. The program consists of 28 members from 1 basic science and 5 clinical departments and 1 College. Peer-reviewed, research funding forthis program totals $9.6 million with $1.5 million coming from the NCI. Program members published 322 cancer-related papers over the prior funding period. Ofthese publications, 16% were intraprogrammatic, 15% were interprogrammatic and 4% were both intra and interprogrammatic, for a total of 36% collaborative publications.
Understanding and manipulating the immune response has great potential for alleviating cancer. Immune cells are a frequent target of the transformation process, with lymphoma a common human cancer, thus understanding how immune cell homeostasis, activation, and death are regulated can contribute important insights in combating these tumors. Additionally, specific manipulation of immune responses is providing new specific, effective, and less toxic therapeutic approaches to controlling and eradicating a large variety of cancers.
|Gorman, Jacob V; Colgan, John D (2018) Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function. Immunology 154:418-433|
|El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68|
|Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653|
|Xiu, Yan; Dong, Qianze; Li, Qingchang et al. (2018) Stabilization of NF-?B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia. Cell Rep 22:350-358|
|Armer, Jessica S; Clevenger, Lauren; Davis, Lauren Z et al. (2018) Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124:3401-3408|
|Mayo, Zachary; Seyedin, Steven; Marquardt, Michael et al. (2018) Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head Neck :|
|D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426|
|McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182|
|Beck, Anna C; Goffredo, Paolo; Hassan, Imran et al. (2018) Risk factors for 30-day readmission after adrenalectomy. Surgery 164:766-773|
|Gu, Chunyan; Holman, Carol; Sompallae, Ramakrishna et al. (2018) Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J 8:22|
Showing the most recent 10 out of 1080 publications